Oryzon Genomics SA ( (ES:ORY) ) has issued an update.
Oryzon Genomics SA has announced a capital increase of 25 million euros through an accelerated private placement to institutional investors. The proceeds will be used to expand clinical development in CNS diseases and oncology, prepare for Phase IIb-III trials, strengthen the balance sheet for potential partnerships, and explore a dual listing on Nasdaq.
More about Oryzon Genomics SA
Oryzon Genomics SA operates in the biotechnology industry, focusing on developing therapies for central nervous system diseases and oncology. The company is engaged in clinical development and drug manufacturing preparations, with a market focus on CNS diseases such as borderline personality disorder and autism spectrum disorder, as well as oncology and hematology.
YTD Price Performance: 79.67%
Average Trading Volume: 2,671
Technical Sentiment Signal: Strong Sell
Current Market Cap: €190.9M
Learn more about ORY stock on TipRanks’ Stock Analysis page.